Quidel Corporation

Halper Sadeh LLP Investigates FLOW, NEOG, CCMP, OCDX, HXOH; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, January 5, 2022

CMC Materials, Inc. (NASDAQ: CCMP)concerning potential violations ofthe federal securities laws and/or breaches of fiduciary duties relating to its sale to Entegris, Inc.

Key Points: 
  • CMC Materials, Inc. (NASDAQ: CCMP)concerning potential violations ofthe federal securities laws and/or breaches of fiduciary duties relating to its sale to Entegris, Inc.
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLPrepresents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

DGAP-News: The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation

Retrieved on: 
Wednesday, January 5, 2022

The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation

Key Points: 
  • The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
    The issuer is solely responsible for the content of this announcement.
  • An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories .
  • Borrelia burgdorferi, the bacterium that causes Lyme disease, is also discussed as a coinfection on this PACE-accredited webinar, the third in a series hosted by Quidel Corporation (Nasdaq: QDEL) in collaboration with Global Lyme Alliance.
  • Dr. Embers currently serves on the 2021 Tick-Borne Disease Working Group, which was established by Congress as part of the 21st Century Cures Act.

The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation

Retrieved on: 
Wednesday, January 5, 2022

An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories .

Key Points: 
  • An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories .
  • Borrelia burgdorferi, the bacterium that causes Lyme disease, is also discussed as a coinfection on this PACE-accredited webinar, the third in a series hosted by Quidel Corporation (Nasdaq: QDEL) in collaboration with Global Lyme Alliance.
  • Her research at Tulane focuses on the effectiveness of antibiotics and other therapeutics to eradicate Borrelia burgdorferi from the body while also exploring the many avenues related to persistent Lyme disease.
  • Dr. Embers currently serves on the 2021 Tick-Borne Disease Working Group, which was established by Congress as part of the 21st Century Cures Act.

Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 4, 2022

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Wednesday, January 12, 2022.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Wednesday, January 12, 2022.
  • Douglas Bryant, president and chief executive officer, will present that day at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) with a question-and-answer session scheduled immediately following the presentation.
  • During the presentation, the company will discuss business and financial developments and trends.
  • The company's statements may contain or constitute material information that has not been previously disclosed.

Halper Sadeh LLP Investigates OCDX, QDEL, FIBK, MNTV; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Tuesday, January 4, 2022

If you are an Ortho shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Ortho shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Global Lateral Flow Assays Market by Application, Product, Technique, End-user, and Region - Forecast to 2026

Retrieved on: 
Thursday, December 30, 2021

The global lateral flow assays market is projected to reach USD 11.4 billion by 2026 from USD 9.6 billion in 2021, at a CAGR of 3.4% during the forecast period.

Key Points: 
  • The global lateral flow assays market is projected to reach USD 11.4 billion by 2026 from USD 9.6 billion in 2021, at a CAGR of 3.4% during the forecast period.
  • Based on product type, the lateral flow assays market is segmented into kits & reagents and lateral flow readers.
  • In 2020, kits & reagents accounted for the larger share of 87.5% of the global lateral flow assays market.
  • Based on technique, the lateral flow assay kits & reagents market is segmented into competitive assays, sandwich assays, and multiplex detection assays.

SHAREHOLDER ALERT: WeissLaw LLP Reminds OCDX, EPAY, MPHX, and CSPR Shareholders About Its Ongoing Investigations

Retrieved on: 
Thursday, December 30, 2021

Under the terms of the merger agreement, EPAY's shareholders will receive $57.00 in cash for each share of EPAY common stock that they hold.

Key Points: 
  • Under the terms of the merger agreement, EPAY's shareholders will receive $57.00 in cash for each share of EPAY common stock that they hold.
  • Under the terms of the merger agreement, MPHX's shareholders will receive 0.74 of a share of Alerus for each MPHX share they own, representing implied per-share merger consideration of approximately $21.94 based upon Alerus's December 29, 2021 closing price of $29.65.
  • Under the terms of the acquisition agreement, CSPR shareholders will receive $6.90 in cash for each share of CSPR common stock that they hold.
  • If you own CSPR shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/cspr
    View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-...

Halper Sadeh LLP Investigates CCMP, QDEL, OCDX; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Thursday, December 30, 2021

If you are a CMC Materials shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a CMC Materials shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Global Lateral Flow Assays Market Forecast to 2026 - Featuring Analysis of Abbott Labs, Roche, Danaher Corp, Siemens, BD, bioMerieux, Bio-Rad Labs, and Thermo Fisher Scientific Amongst Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 29, 2021

The global lateral flow assays market is projected to reach USD 11.4 billion by 2026 from USD 9.6 billion in 2021, at a CAGR of 3.4% during the forecast period.

Key Points: 
  • The global lateral flow assays market is projected to reach USD 11.4 billion by 2026 from USD 9.6 billion in 2021, at a CAGR of 3.4% during the forecast period.
  • Based on product type, the lateral flow assays market is segmented into kits & reagents and lateral flow readers.
  • In 2020, kits & reagents accounted for the larger share of 87.5% of the global lateral flow assays market.
  • Based on technique, the lateral flow assay kits & reagents market is segmented into competitive assays, sandwich assays, and multiplex detection assays.

Quidel’s Antigen Tests Detect the Omicron Variant

Retrieved on: 
Tuesday, December 28, 2021

At Quidel, we continuously monitor the evolution and activity of COVID-19 variants in circulation, and the Omicron variant is no exception.

Key Points: 
  • At Quidel, we continuously monitor the evolution and activity of COVID-19 variants in circulation, and the Omicron variant is no exception.
  • Recent testing using live South African samples confirmed that our QuickVue At-Home OTC COVID-19 Test and our Sofia SARS Antigen FIA are detecting the SARS-CoV-2 Omicron variant.
  • On December 22, 2021, the Food and Drug Administration (FDA) indicated that data generated in preliminary RADx laboratory studies, with heat-inactivated Omicron samples, suggested that the QuickVue antigen tests are able to detect the Omicron variant with similar performance as with other variants.
  • These data also suggest that the QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants.